

NONALCOHOLIC STEATOHEPATITIS AND ATRIAL FIBRILLATION: BASELINE CHARACTERISTICS AND OUTCOMES: A PROPENSITY-MATCHED ANALYSIS FROM NATIONAL INPATIENT SAMPLE DATABASE



Himanshu Kavani¹, Kirtenkumar Patel¹, Abdalrahman Assaassa¹, Devina Adalja², Krunalkumar Patel¹, Tulika Garg¹, Nishi Patel¹, Umang Patel¹

1. St Mary Medical Center, 2. St. Joseph's Regional Medical Center

INTRODUCTION

- Non-alcoholic steatohepatitis (NASH) affects at least 3 to 5% of Americans, which imposes a higher risk of concurrent cardiovascular diseases including arrhythmias, of which atrial fibrillation (Afib) is the most prevalent.
- Nonetheless, data on the burden of concurrent Afib in NASH patients is still lacking. Our aim is to define baseline characteristics of NASH patients with and without Afib and related in-hospital outcomes such as mortality, length of stay (LOS), and total hospital costs.

METHODS

- Using the National Inpatient Sample database, we analyzed all NASH-related adult hospitalizations with or without Afib from September 2015 to December 2020.
- We applied propensity score matching to the 2 groups to balance baseline characteristics.
- SAS 9.4 software was used for statistical analysis.

RESULTS

- Out of 435,845 NASH hospitalizations, 62,335 (14.3 %) had concurrent Afib. The NASH with Afib cohort consisted of older patients (mean age, 69.4 vs. 60.6 years) compared to those without Afib (p< 0.001). NASH with the Afib cohort had more females (54.5%) and Caucasians (82.5%).
- NASH patients with Afib had an almost 3-times higher prevalence of congestive heart failure (52.5% vs. 17.1%)(p< 0.001) and almost 2-times higher prevalence of coronary artery disease (40.2% vs. 20.2%), Peripheral vascular disease (7.5% vs 4.1%), and Renal failure (42.6% vs 24.7%) (p< 0.001). Moreover, NASH patients with Afib had higher prevalence of hypertension (65.7% 61.9%), Diabetes mellitus (64% vs 60.9%), COPD (28.5% vs 21.2%), and obesity (39.3% vs 36.3%).
- Compared to the NASH without Afib cohort, the NASH with Afib cohort had higher mortality (6.5% vs.4.1%) with a mortality-adjusted odds ratio of 1.63 (95% CI: 1.55-1.71) (p< 0.001).
- In addition, the mean LOS(6.8 vs. 5.9), and mean hospital cost (\$ 18701 vs. \$16,220) were also higher (p< 0.001).

TABLES

Table 1. Baseline characteristics of Nonalcoholic Steatohepatitis with Atrial Fibrillation and without Atrial Fibrillation

| Fibriliation and with | out Atriai Fibrillation | | |
|-----------------------------|-----------------------------------|---------------------------------------|----------|
| Variables | NASH with Afib N=62,335(14.3%) | NASH without Afib N=373,510(85.7%) | P- Value |
| Age, in years (Mean ± SD) | 69.4 ± 10.2 | 60.6 ± 13.2 | <0.001 |
| Age groups, % | | | <0.001 |
| 18 - 34 years | 0.4% | 4.6% | |
| 35 – 49 years | 3.3% | 14.1% | |
| 50 – 64 years | 24.5% | 38.6% | |
| 65 – 79 | 56.0% | 37.5% | |
| >79 years | 15.8% | 5.1% | |
| Gender, % | | | < 0.001 |
| Male | 45.5% | 36.8% | |
| Female | 54.5% | 63.2% | |
| Race, % | | | <0.001 |
| Caucasians | 82.0% | 73.5% | |
| African Americans | 3.5% | 4.3% | |
| Others | 14.5% | 22.2% | |
| Comorbidities, % | | | |
| Hypertension | 65.7% | 61.9% | < 0.001 |
| Diabetes mellitus | 64% | 60.9% | < 0.001 |
| Congestive heart failure | 52.2% | 17.1% | < 0.001 |
| CAD | 40.2% | 20.2% | <0.001 |
| Peripheral vascular disease | 7.5% | 4.1% | <0.001 |
| COPD | 28.5% | 21.2% | <0.001 |
| Renal failure | 42.6% | 24.7% | < 0.001 |
| Coagulopathy | 32% | 32.5% | 0.01 |
| Obesity | 39.3% | 36.3% | <0.001 |
| Drug abuse | 1.5% | 2.5% | < 0.001 |
| Alcohol abuse | 2.3% | 3.9% | < 0.001 |
| Smoking | 30.5% | 32.1% | <0.001 |
| Insurance type, % | | | <0.001 |
| Medicare | 75.2% | 53.6% | |
| Medicaid | 5.4% | 13% | |
| Private | 16.4% | 27.8% | |
| Other | 3% | 5.5% | |
| Location/Teaching status of | | | z0.001 |
| the hospital, % | | | <0.001 |
| Rural | 7.7% | 7.6% | |
| Urban nonteaching | 19.5% | 18.1% | |
| Urban teaching | 72.8% | 74.3% | |

Table 2. Propensity Matched Outcomes of Nonalcoholic Steatohepatitis with Atrial Fibrillation and without Atrial Fibrillation

| Propensity-Matched Outcomes | NASH with Afib N=62175 | NASH without Afib N= 62190 | P-value |
|---|---------------------------|-------------------------------|---------|
| In-hospital mortality, % | 6.5% | 4.1% | <0.001 |
| Mortality adjusted odds ratio | 1.63 (1.55 – 1.71) | | <0.001 |
| Length of stay, in days (mean ± SD) | 6.8 ± 7.5 | 5.9 ± 6.3 | <0.001 |
| Total hospitalization cost, in US \$ (mean ± SD) | 18701 ± 28527 | 16220 ± 26589 | <0.001 |
| Disposition, % | | | <0.001 |
| Discharge to home | 40.3% | 45.3% | |
| Transfer other: includes Skilled Nursing Facility, Intermediate Care Facility, or another type of facility | 26.5% | 23.6% | |
| Home health care | 23% | 23.7% | |
| Against medical advice | 0.4% | 0.4% | |

CONCLUSION

Our results indicate a higher burden imposed by the presence of Afib in NASH patients. The NASH with Afib cohort had significantly higher inhospital mortality, mean length of stay, and hospitalization cost. This conclusion supports the need for further studies to better illustrate the pathogenesis, early diagnosis, possible preventive measures, and treatment modalities tailored towards NASH-associated Afib.

The primary author and the coauthors have no disclosures.

For questions, please email Himanshu.Kavani@stmaryhealthcare.org